Filing Flows › Rani Therapeutics Holdings (RANI) › Q4 2025
Rani Therapeutics Holdings (RANI) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 26, 2026
Rani Therapeutics Holdings (RANI) reported revenue of $1.5M for the fourth quarter 2025 (Q4 2025), +42% from a year earlier. Operating margin was -584.2%, net loss $9.1M (621.1% of revenue).
Rani Therapeutics Holdings, Q4 2025: revenue $1.5M (+42% year over year), operating margin -584.2%, net loss $9.1M, operating cash flow $294K. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.5M | — | +42% |
| Operating profit | −$8.5M | — | — |
| Net earnings | −$9.1M | — | — |
| Operating cash flow | $294K | — | — |
What changed
Revenue was $1.5M in Q4 2025, up 42% year over year.
Operating costs exceeded revenue by $8.5M, an operating margin of -584.2%. Total costs fell 37% while revenue rose 42%. The quarter ended with a net loss of $9.1M.
Operating cash flow was $294K. Non-cash charges added back $186K of depreciation and amortization and $2.2M of share-based compensation. Working capital and other items added $6.9M.
Questions
What was Rani Therapeutics Holdings' revenue in the fourth quarter 2025?
Rani Therapeutics Holdings (RANI) reported revenue of $1.5M for the fourth quarter 2025 (Q4 2025), +42% from a year earlier.
Was Rani Therapeutics Holdings profitable in the fourth quarter 2025?
Operating loss was $8.5M (-584.2% of revenue) and net loss $9.1M.